ACCG-2671

ACCG-2671 is an investigational oral small molecule drug developed by Structure Therapeutics for the treatment of obesity and related metabolic diseases. It acts as a Dual Amylin and Calcitonin Receptor Agonist (DACRA), targeting both the amylin receptor and the calcitonin receptor. Amylin is a hormone involved in regulating glycemia, energy balance, appetite, satiety, leptin sensitivity, and energy expenditure. By activating these receptors, ACCG-2671 aims to reduce food intake, slow gastric emptying, promote weight loss, preserve lean mass, and improve metabolic health. Preclinical studies have demonstrated potent target engagement with robust weight loss effects and a favorable safety profile supportive of once-daily oral dosing in humans. ACCG-2671 is expected to enter Phase 1 clinical development by the end of 2025[1][3][4][5][6].